Switch theme
Sign up to access all valuation multiples
ViroGates AS is a life science company that develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular, to make a clinical decision on hospitalization or discharge of emergency patients. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, and cancer. It has developed a product line called suPARnostic to make the suPAR test available as a commercially available test and the ambition is to get the test implemented and used for clinical decision-making.
2000
10
Last FY Revenue $1.1M
Last FY EBITDA -$2.2M
$8.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, ViroGates achieved revenue of $1.1M and an EBITDA of -$2.2M.
ViroGates expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ViroGates valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $0.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 67% | XXX | XXX | XXX |
| EBITDA | XXX | -$2.2M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -203% | XXX | XXX | XXX |
| EBIT | XXX | -$2.2M | XXX | XXX | XXX |
| EBIT Margin | XXX | -204% | XXX | XXX | XXX |
| Net Profit | XXX | -$2.2M | XXX | XXX | XXX |
| Net Margin | XXX | -201% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ViroGates's stock price is DKK 8 (or $1).
ViroGates has current market cap of DKK 62.8M (or $9.5M), and EV of DKK 56.9M (or $8.6M).
See ViroGates trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.6M | $9.5M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ViroGates has market cap of $9.5M and EV of $8.6M.
ViroGates's trades at 8.0x EV/Revenue multiple, and -3.9x EV/EBITDA.
Equity research analysts estimate ViroGates's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ViroGates's P/E ratio is not available.
See valuation multiples for ViroGates and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.5M | XXX | $9.5M | XXX | XXX | XXX |
| EV (current) | $8.6M | XXX | $8.6M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -4.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialViroGates's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
ViroGates's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ViroGates's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ViroGates and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -203% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 122% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 97% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 271% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ViroGates acquired XXX companies to date.
Last acquisition by ViroGates was XXXXXXXX, XXXXX XXXXX XXXXXX . ViroGates acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ViroGates founded? | ViroGates was founded in 2000. |
| Where is ViroGates headquartered? | ViroGates is headquartered in Denmark. |
| How many employees does ViroGates have? | As of today, ViroGates has 10 employees. |
| Is ViroGates publicy listed? | Yes, ViroGates is a public company listed on CSE. |
| What is the stock symbol of ViroGates? | ViroGates trades under VIRO ticker. |
| When did ViroGates go public? | ViroGates went public in 2018. |
| Who are competitors of ViroGates? | Similar companies to ViroGates include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of ViroGates? | ViroGates's current market cap is $9.5M |
| Is ViroGates profitable? | Yes, ViroGates is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
